CELLDEX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.92 USD | -2.78% |
|
-6.20% | +0.66% |
| 05-06 | Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000 | MT |
| 05-06 | Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 37.27 | 693.2 | 1,803 | 2,099 | 2,169 | 2,631 | - | - |
| Enterprise Value (EV) 1 | 37.27 | 693.2 | 1,395 | 1,794 | 1,745 | 2,631 | 2,631 | 2,631 |
| P/E ratio | -0.64 x | -8.67 x | -23.6 x | -18.6 x | -13.6 x | -17.2 x | -13.9 x | -12.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.4 x | 93.5 x | 388 x | 891 x | 315 x | 918 x | 707 x | 774 x |
| EV / Revenue | 10.4 x | 93.5 x | 388 x | 891 x | 315 x | 918 x | 707 x | 774 x |
| EV / EBITDA | - | - | - | - | -14 x | -15.4 x | -12 x | - |
| EV / FCF | - | - | -29 x | -19.9 x | -19.9 x | -18.1 x | -15.3 x | -12 x |
| FCF Yield | - | - | -3.45% | -5.03% | -5.03% | -5.51% | -6.54% | -8.32% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,713 | 39,567 | 46,664 | 47,100 | 54,689 | 65,911 | - | - |
| Reference price 2 | 2.230 | 17.52 | 38.64 | 44.57 | 39.66 | 39.92 | 39.92 | 39.92 |
| Announcement Date | 20-03-26 | 21-03-29 | 22-02-28 | 23-02-28 | 24-02-26 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.573 | 7.418 | 4.651 | 2.357 | 6.883 | 2.867 | 3.72 | 3.4 |
| EBITDA 1 | - | - | - | - | -154.5 | -170.4 | -219.8 | - |
| EBIT 1 | -55.03 | -63.35 | -71.24 | -115.2 | -142 | -176 | -203.8 | -230.6 |
| Operating Margin | -1,540.19% | -854.06% | -1,531.78% | -4,889.01% | -2,063.66% | -6,140.23% | -5,477.42% | -6,780.88% |
| Earnings before Tax (EBT) 1 | -50.88 | -60.95 | -70.74 | -112.3 | -141.4 | -155.4 | -196.8 | -224 |
| Net income 1 | -50.88 | -59.78 | -70.51 | -112.3 | -141.4 | -153.1 | -195.8 | -229.8 |
| Net margin | -1,423.96% | -805.88% | -1,516.04% | -4,765.59% | -2,054.76% | -5,341.85% | -5,263.44% | -6,758.82% |
| EPS 2 | -3.510 | -2.020 | -1.640 | -2.400 | -2.920 | -2.315 | -2.874 | -3.218 |
| Free Cash Flow 1 | - | - | -62.16 | -105.6 | -109.1 | -145 | -172 | -219 |
| FCF margin | - | - | -1,336.44% | -4,478.57% | -1,585.2% | -5,058.13% | -4,623.66% | -6,441.18% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-26 | 21-03-29 | 22-02-28 | 23-02-28 | 24-02-26 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.333 | 0.174 | 0.163 | 0.407 | 1.613 | 0.967 | 0.268 | 1.517 | 4.132 | 0.156 | 1 | 2.28 | 1 | 1 | 1.3 | 1.3 |
| EBITDA 1 | - | - | - | - | - | - | - | - | -47.63 | - | -41.3 | - | -43.7 | -44.8 | - | - |
| EBIT 1 | -20.34 | -23.79 | -27.72 | -27.7 | -27.88 | -32.47 | -33.2 | -41.24 | -35.13 | -40.61 | -43.02 | - | -45.88 | -47.8 | -56.8 | -56.8 |
| Operating Margin | -6,108.11% | -13,674.14% | -17,007.36% | -6,804.91% | -1,728.77% | -3,357.91% | -12,389.93% | -2,718.46% | -850.12% | -26,030.77% | -4,302.5% | - | -4,587.5% | -4,780% | -4,369.23% | -4,369.23% |
| Earnings before Tax (EBT) 1 | -20.15 | -23.05 | -36 | -26.78 | -26.49 | -29.36 | -30.5 | -38.26 | -43.31 | -32.81 | -38.24 | - | -41.28 | -43.06 | -56.8 | -56.8 |
| Net income 1 | -20.15 | -23.05 | -36 | -26.78 | -26.49 | -29.36 | -30.5 | -38.26 | -43.31 | -32.81 | -37.45 | - | -40.35 | -42.65 | -56.8 | -56.8 |
| Net margin | -6,050.45% | -13,247.13% | -22,088.34% | -6,580.84% | -1,642.1% | -3,036.3% | -11,381.34% | -2,522.08% | -1,048.06% | -21,030.77% | -3,745% | - | -4,035% | -4,265% | -4,369.23% | -4,369.23% |
| EPS 2 | -0.4300 | -0.4900 | -0.7700 | -0.5700 | -0.5600 | -0.6200 | -0.6500 | -0.8100 | -0.8300 | -0.5600 | -0.5775 | - | -0.5925 | -0.6175 | -0.8600 | -0.8600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-02-28 | 22-05-05 | 22-08-08 | 22-11-09 | 23-02-28 | 23-05-04 | 23-08-08 | 23-11-02 | 24-02-26 | 24-05-06 | - | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | 408 | 305 | 424 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62.2 | -106 | -109 | -145 | -172 | -219 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | 1.25 | - | 1.82 | 1 | 1.5 | 2 |
| Capex / Sales | - | - | 26.85% | - | 26.41% | 34.88% | 40.32% | 58.82% |
| Announcement Date | 20-03-26 | 21-03-29 | 22-02-28 | 23-02-28 | 24-02-26 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
39.92
USD
Average target price
69
USD
Spread / Average Target
+72.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.66% | 2.63B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CLDX Stock
- Financials Celldex Therapeutics, Inc.
